Zura BioZURA
About: Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Employees: 30
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
1.18% more ownership
Funds ownership: 65.69% [Q4 2024] → 66.87% (+1.18%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
14% less funds holding
Funds holding: 87 [Q4 2024] → 75 (-12) [Q1 2025]
45% less capital invested
Capital invested by funds: $107M [Q4 2024] → $59M (-$48.3M) [Q1 2025]
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Oppenheimer Jeff Jones | 1,198%upside $17 | Outperform Maintained | 9 May 2025 |
Financial journalist opinion









